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stratiﬁed by ulcer healing status. Work productivity loss was
captured weekly by the Work Productivity and Activity Impair-
ment (WPAI) Questionnaire [1] speciﬁc for VLU. RESULTS: The
mean direct medical cost of treating VLU during the study period
was estimated to be $1772 per patient for US payers, $1294 for
US providers, and £1502 in the UK. The largest direct medical
cost component was for professional services, or labor (approxi-
mately 70%), followed by dressing, compression bandages, and
medications. Patients who had at least one ulcer not healed at the
end of study had higher mean costs compared to those patients
who had all ulcers healed ($2250 vs. $1012 from the US payer
perspective, $1625 vs. $862 from the US provider perspective,
and £1770 vs. £965 from the UK NHS perspective). Over the
12-week study duration, more reductions in work productivity
loss and activity impairment were found in the healed group vs.
the non-healed group. CONCLUSIONS: VLU imposes signiﬁ-
cant medical costs and work productivity losses. Since the cost of
professional services is the main cost driver in the treatment of
VLU, new technologies that reduce the professional labor time
could signiﬁcantly reduce the economic burden of venous leg
ulcer. [1] Reilly MC, Zbrozek AS, Dukes EM. The validity and
reproducibility of work productivity and activity impairment
instrument. Pharmacoeconomics 1993;4:353–65.
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OBJECTIVES: This study aims to assess if hepatitis C patients
who had previously failed to achieve sustained virologic response
(SVR) following any hepatitis C treatment demonstrate different
patterns of health care utilization versus treatment-naïve patients
after peginterferon plus ribavirin (PR) therapy in the European
Union. METHODS: A retrospective chart review of hepatitis C
patients who received PR was conducted in the UK, Germany,
France, Italy, and Spain. Descriptive analyses reported standard-
ized annual rates of hospitalizations, emergency/accident visits
(EA), family physician/general practitioner visits (GP), specialist
visits (SP), and having 5 clinical tests (TESTS). Logistic regres-
sion models were applied to assess TF status impact on afore-
mentioned outcomes. RESULTS: 165 physicians collected data
for 615 patients (baseline data: mean age 43.7 years, 33%
female, 90% Caucasian, 85% genotype-1, 26% viral load
>1,000,000 IU/mL, 25% with prior treatment failure [TF]). PR
was administered for a median of 9.1 months (interquartile
range: 5.3–11.9); median post-treatment follow-up was 6.0
months (interquartile range: 2.0–10.0). Fewer TF patients
achieved SVR than treatment-naïve patients (43.3% versus
58.3%). Compared with treatment-naïve patients, TF patients
had signiﬁcantly more annual hospitalizations (1.7 versus 0.3),
EA (0.7 versus 0.2), GP (4.3 versus 2.0), SP (4.1 versus 2.3), and
TESTS (75% versus 85%) (p < 0.05 for all). When controlling
for confounding factors (age, weight, gender, genotype, time
between diagnosis and treatment initiation, alcohol intake, past
intravenous drug use, pre-treatment liver biopsy, steatosis, pre-
viral RNA, and SVR status), TF remained an independent risk
factor for signiﬁcant risk of hospitalization (OR = 4.33, 95%
CI = 2.38–7.87), EA (OR = 2.63, 95% CI = 1.49–4.76), GP
(OR = 3.45, 95% CI = 2.04–5.56), SP (OR = 2.86, 95%
CI = 1.72–4.76) and TESTS (OR = 2.04, 95% CI = 1.14–3.70).
Similar results were found in the genotype-1 patients. CONCLU-
SIONS: Hepatitis C patients who failed prior treatment demon-
strate higher health care resource use than treatment-naïve
patients after PR therapy, regardless of SVR status.
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OBJECTIVES: DUET 1&2 are two identically designed,
ongoing, randomized, double-blind, placebo-controlled, phase
III trials, which have demonstrated superiority of etravirine
(TMC125, ETR) + background regimen (BR) versus placebo +
BR in HIV-1-infected, treatment-experienced patients. This
analysis estimates the cost of the hospitalizations observed in
the DUET studies applied to a Belgian treatment setting.
METHODS: Hospitalization events and duration of hospital
stay were recorded for each patient in the DUET trials. Differ-
ences in hospitalizations and total days hospitalized at 48 weeks
were compared between ETR + BR and placebo + BR in the
pooled DUET population. Daily hospital costs were collected
from the Belgian IMS Hospital Disease database, a longitudinal
patient-level retrospective database. A sample of 277 HIV
patients with 397 hospitalizations in Belgium were extracted.
An average cost per day was calculated in 2007 Euros, which
included INAMI (health system cost) and patient contribution
costs for medications, procedures, and rooming charges. These
costs were applied to the total days observed in the DUET trials
to estimate overall hospital costs. RESULTS: A total of 1203
patients were included from the DUET trials: 599 vs. 604 in the
ETR vs. placebo groups. Baseline characteristics and average
follow-up were comparable between arms. The number (%) of
patients hospitalized was 105 (18%) for ETR + BR vs. 139
(23%) for placebo + BR, respectively (p = 0.0006). Total hospital
days observed during the 48 week follow-up period were 1702
for ETR + BR vs. 2747 for placebo + BR. The average cost per
patient day was estimated to be €556.39. Over the population,
total hospital costs were estimated to be €946,676 for ETR + BR
vs. €1,528,403 for placebo + BR. CONCLUSIONS: At Week 48,
ETR + BR provided a statistically signiﬁcant reduction the
number of patients hospitalized vs. placebo + BR. The reductions
in the number of hospitalizations and time spent in the hospital
represent clinical beneﬁt to the patients and signiﬁcant savings in
hospital-related costs to the health care system.
INFECTION—Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the impact of communication between
physicians and patients living with HIV/AIDS on levels of treat-
ment adherence and patient satisfaction. METHODS: In a pre-
vious survey at our teaching hospital in Thailand we found good
adherence in 99% of patients, assessed by visual analogue scale.
This qualitative study was conducted between November 2007–
January 2008. The research comprised direct observations of
patient-health care provider encounters at the clinic and in-depth
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interviews with 14 key informants including patients and their
spouses. Interview responses were recorded, transcribed and
organized thematically based on emerging codes using an induc-
tive analysis. Discussion with attending physicians, nurses, and
pharmacists at the clinic was also incorporated as data triangu-
lation. RESULTS: Potential problems in the patient-provider
communication included unfriendly welcoming or disgusted
reactions; disclosure of conﬁdential matters; and health care
environment factors. Compared with their previous experiences
at other health care facilities, the patients were very satisﬁed with
genuine and empathetic providers at this site. Moreover, they
perceived that the providers were more highly trained specialists
with effective communication skills, which encouraged the
patients to ask questions regarding their health. In addition, a
hotline number was provided so the patients could contact the
clinic whenever they encountered any health-related problems or
needed assistance. Thus, a trusted therapeutic rapport was estab-
lished with a positive impact on the patient-physician’s commit-
ment to care which resulted a good adherence. CONCLUSIONS:
Provider-patient communication contributes to patient satisfac-
tion with medical treatment which is extremely important in
HIV/AIDS care. As numerous issues facilitate or inhibit construc-
tive relationships between providers and patients, it is essential
for doctors to be aware of their power when dealing with
patients, particularly in this consumer empowerment era. Good
communication is essential to good practice of medicine and its
rewards are immeasurable for both patients and providers.
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OBJECTIVES: To assess the health-related quality of life
(HRQoL) among patients with venous leg ulcer (VLU) in the US
and UK. METHODS: A prospective, observational, multi-center
study was conducted among 112 patients with VLU in the US
(76 patients) and the UK (36 patients) between 2007 and 2008.
Patients completed a generic health status measure, the EuroQol
(EQ-5D) Questionnaire1 and a disease-speciﬁc health-related
quality of life measure, the Charing Cross Leg Ulcer Question-
naire2 at study baseline and at the end of the study. Patients
were provided routine medical care for their ulcer for a study
period of 12 weeks or until all their ulcers healed. Analyses
were conducted to assess the change in HRQoL scores over the
study period among all patients, among patients with all ulcers
healed (healed patients) and among patients with at least one
ulcer not healed (non-healed patients). RESULTS: The mean age
(SD) of VLU patients was 61.9 (13.7) years in the US and was
70.9 (13.9) years in the UK. A total of 51.3% of VLU patients
in the US were males while 36.1% in the UK were males. At
baseline, the mean (SD) EQ-5D index score was 0.6628
(0.2402) for US patients and 0.6206 (0.3413) for UK patients.
There was a statistically signiﬁcant improvement in EQ-5D
index scores over the study period among the US healed patients
(p < 0.01) but not for US non-healed patients or UK patients.
Among all patients, the Charing Cross Leg Ulcer Questionnaire
showed that patients’ social interaction (p < 0.01) and emo-
tional status (p < 0.01) were signiﬁcantly improved during the
study period. CONCLUSIONS: VLU results in a signiﬁcant
negative impact on patients’ health status. Treatments for VLU
that promote ulcer healing are likely to result in signiﬁcant
improvements in patients’ health-related quality of life. EU-08–
1532. © 2008 ER. Squibb & Sons, LL.C. 1 The EuroQuol
Group. www.euroqol.org; accessed 01/02/2007 2 Smith J, et al.
Measuring the quality of life in patients with venous leg ulcers.
J Vasc Surg 2000;31:642–9.
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OBJECTIVES: To document the psychometric properties and
estimate a minimal important difference (MID) for the Sinonasal
Outcome Test-16 (SNOT-16) in patients with acute bacterial
sinusitis. METHODS: Secondary psychometric analysis was
undertaken on data from a phase III trial to evaluate the efﬁcacy
and safety of moxiﬂoxacin over 5 consecutive days in the treat-
ment of acute bacterial sinusitis (N = 374). Trial patients also
completed the RAND SF-36, the Activity Impairment Assess-
ment (AIA) and a global rating of change. The SNOT-16 has 16
items and is scored as a uni-dimensional measure of symptoms
of rhinosinusitis. Internal consistency and construct validity
(against SF-36 and AIA) were assessed at baseline. Sensitivity and
MID were assessed by comparing test of cure data against base-
line using statistical methods (effect size (ES), standardised
response mean (SRM); and standard error of measurement
(SEM) and 1/2 standard deviation (1/2SD)) and anchor methods
against the smallest change on the global rating of change.
Missing data were imputed using last observation carried
forward. RESULTS: Internal consistency (a = 0.874) and con-
struct validity (SF-36 Role Function r = -0.44; Vitality r = 0.45,
Social Function r = 0.48, Pain r = 0.51, AIA r = 0.67 all P <
0.001) were conﬁrmed. The SNOT-16 was sensitive (ES = 1.68;
SRM = 1.36). The MID estimated by the anchor method was
-0.85; but MID was lower by distributional estimates
(SEM = 0.21, 1/2SD = 0.29). CONCLUSIONS: The study con-
ﬁrms the good psychometric properties of the SNOT-16 in
patients with acute bacterial sinusitis and demonstrates the sen-
sitivity and MID for this measure. The 3 MID estimates were
widely separated and the higher anchor based estimate was
settled on.
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OBJECTIVES: To document the psychometric properties and
estimate a minimal important difference (MID) for the Activity
Impairment Assessment (AIA) questionnaire in patients with
acute bacterial sinusitis. The AIA has previously been validated
in people with uncomplicated urinary tract infections.
METHODS: Secondary psychometric analysis was undertaken
on data from a phase III trial to evaluate the efﬁcacy and safety
of moxiﬂoxacin over 5 consecutive days in the treatment of acute
bacterial sinusitis (N = 374). Trial patients also completed the
RAND SF-36, the Sinonasal Outcomes Test-16 (SNOT-16) and a
global rating of change. The AIA has 5 items and is scored as a
uni-dimensional measure of the impact of disease on an individu-
al’s work or regular activities. Internal consistency and construct
validity (against SF-36 and SNOT-16) were assessed at baseline.
Sensitivity and MID were assessed by comparing test of cure data
against baseline using statistical methods (effect size (ES), stan-
dardised response mean (SRM); and standard error of measure-
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